GlobeStar Therapeutics Corp (GSTC)

[SILVERSURFER4263]

Was there an initial clinical study?


Yes. The initial study consisted of 150 volunteers, 90 subjects ages (25-65) with MS between 5-20 years (including 60 control volunteers). They used Barthel Index (used as a mobility disability index). They also used a scale for muscle imbalance (Kendall Scale), before and after treatment.

The subjects received 2 doses/day for 45 days, along with a controlled diet.





Fabrizio de Silvestri (https://patents.justia.com/inventor/fabrizio-de-silvestri) is a lawyer by trade (1998), but suffers, himself, from Multiple Sclerosis. In 2005, he started studying forensic medicine. He researched to try to find a better therapy filing the patent in 2015 (Applied in 2014). In regard to speaking about the therapy itself, he said,

My patented formula is a composition for treating neurodegeneration, including an antibiotic, an antifungal agent, and a lipophilic potentiating agent in synergistically effective amounts.